| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Research and development | 802,994 | - |
| Salaries | 375,000 | - |
| Insurance | 214,970 | - |
| Stock-based compensation | 210,684 | - |
| Operating expenses | 894,720 | - |
| Interest income | 74,020 | - |
| Net loss | -2,424,348 | -1,757,611 |
| Stock-based compensation | 210,684 | 123,504 |
| Change in fair value of warrant liability | -3,469 | -2,257 |
| Research and development contract liabilities | - | 0 |
| Advances on research and development contract services | 37,773 | 49,087 |
| Prepaid insurance and prepaid expenses | -196,750 | -125,403 |
| Accrued legal settlement | - | 0 |
| Accounts payable and accrued expenses | 6,222 | 76,870 |
| Net cash used in operating activities | -1,976,388 | -1,385,004 |
| Exercise of pre-funded warrants | - | 0 |
| Proceeds from issuance of common shares from atm, net of costs | 347,549 | 347,549 |
| Proceeds from sale of common stock, warrants, and pre-funded warrants in public offering, net of offering costs | 4,352,792 | 4,352,792 |
| Net cash provided by financing activities | 4,700,341 | 4,700,341 |
| Net increase in cash | 2,723,953 | 3,315,337 |
| Cash and cash equivalents at beginning of period | 3,325,131 | - |
| Cash and cash equivalents at end of period | 6,049,084 | - |
Bone Biologics Corp (BBLGW)
Bone Biologics Corp (BBLGW)